Argenta allies with PRECOS to offer drug discover services

23 February 2009

The UK's Argenta Discovery and contract research organization PRECOS have entered into an alliance to provide cancer drug discovery services.   Christopher Ashton, chief executive of Argenta, said: "Argenta has  partnered with PRECOS to provide clients with dedicated access to  specialist in vitro, ex vivo and in vivo cancer models and expertise,  offered by a world leader in the field. We have several ongoing  cancer-focused contract research programs and a number of projects in  the pipeline, which are likely to benefit from PRECOS' support and  know-how."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight